Every material Form 8-K CEL SCI CORP has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CEL-SCI sold 2,500,000 common shares at $1.00 per share in a best-efforts offering through placement agent ThinkEquity, which closed on June 16, 2026, for gross proceeds of $2.5 million before fees and expenses. The company plans to use the net proceeds for development of Multikine, general corporate purposes and working capital. Existing shareholders will own a larger share of the company after the new shares are issued.
2,500,000 shares sold at $1.00 per share; gross proceeds of $2.5 million before placement fees and expenses
Placement agent cash fee of 7.0% of gross proceeds, plus reimbursement of agent expenses of up to $67,000
Company agreed not to issue additional shares or securities for 30 days from June 16, 2026, subject to exceptions
Directors and officers agreed to a 45-day lock-up from June 14, 2026, subject to exceptions
CEL-SCI entered a strategic partnership, distribution, and revenue sharing agreement with Amarox covering regulatory affairs, marketing, and potential commercialization of Multikine for head and neck cancer in Saudi Arabia. The companies will share net revenue from Saudi sales 50%/50%, but the filing gives no dollar amounts, and Multikine is not yet approved for sale in any market.
Agreement announced May 11, 2026; 8-K dated May 14, 2026
Net revenue from Multikine sales in Saudi Arabia to be shared 50%/50%, with the revenue share tied to receipt of Breakthrough Medicine Designation from the SFDA
Amarox to act as local regulatory representative and to become exclusive commercial distributor upon SFDA approval, with an optional extension to GCC countries
CEL-SCI Corporation sold 6,000,000 common shares at $1.20 per share under a registered offering with ThinkEquity as placement agent, for gross proceeds of approximately $7.2 million before placement fees and expenses. The offering closed on May 13, 2026, and the company plans to use the net proceeds for Multikine development, general corporate purposes and working capital. The sale adds 6,000,000 shares to the company's common stock outstanding, which dilutes existing shareholders.
6,000,000 shares sold at $1.20 per share; agreement entered May 11, 2026; offering closed May 13, 2026
Gross proceeds approximately $7.2 million, before placement agent fees and offering expenses
Placement agent cash fee of 7.0% of gross proceeds, plus expense reimbursement up to $150,000
Company agreed not to issue additional shares for 30 days from May 13, 2026; directors and officers agreed to a 45-day lock-up from May 11, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CEL SCI CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →